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Summary
Background.— The AntiPlatelet Therapy Observational Registry (APTOR) was a prospective
observational study of acute coronary syndrome (ACS) patients undergoing percutaneous coro-
nary intervention (PCI) in France, Spain, and the UK.
Abbreviations: ACC, American College of Cardiology; ACE, Angiotensin-converting enzyme inhibitor; ACS, Acute coronary syndrome;
FSSAPS, Agence franc¸aise de sécurité sanitaire des produits de santé; AHA, American Heart Association; APTOR, AntiPlatelet Therapy
bservational Registry; ARB, Angiotensin 2 receptor blocker; BMI, Body mass index; BMS, Bare metal stent; CABG, Coronary artery bypass
rafting; CHD, Coronary heart disease; CI, Conﬁdence interval; CRO, Contract research organisation; DES, Drug eluting stent; ESC, European
ociety of Cardiology; GPI IIb/IIIa, Glycoprotein IIb/IIIa inhibitor; IQR, Interquartile range; MI, Myocardial infarction; NSTEMI, Non-ST-
egment elevation myocardial infarction; OR, Odds ratio; PCI, Percutaneous coronary intervention; STEMI, ST-segment elevation myocardial
nfarction; T, Time; UA, Unstable angina; UK, United Kingdom.
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Aims.— To evaluate patterns of ACS healthcare use, focusing on APTOR results from France.
Methods.— Consecutive presenting ACS patients requiring PCI were recruited between January
and August 2007. Treatments and outcomes were recorded from the qualifying ACS event to
12months follow-up.
Results.— In France, qualifying diagnosis was unstable angina/non-ST-segment elevation
myocardial infarction (UA/NSTEMI) in 255 (53%) patients and ST-segment elevation myocar-
dial infarction (STEMI) in 228 (47%) patients. Ninety-six percent underwent PCI with stent
implantation. Drug eluting stents were used less frequently in France (22%) than Spain (54%)
or the UK (42%). In France, antiplatelets were more frequently received in the ambu-
lance (21%); a 200—299mg aspirin-loading dose was most frequently received (50%) and
more than a third of patients received a clopidogrel-loading dose of over 300mg (34%). At
12months in France, 86% were still receiving aspirin, 75% clopidogrel, and 73% combination
treatment.
Conclusion.— There was considerable country-variation in ACS management. These results pro-
vide a benchmark of physician practice to compare with guidelines.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé
Contexte.— AntiPlatelet Therapy Observational Registry (APTOR) était une étude observation-
nelle prospective des patients avec un syndrome coronarien aigu (SCA) traités par angioplastie
coronarienne percutanée (ICP) en France, Espagne et Angleterre.
Objectifs.— Évaluer les tendances d’utilisation de soins pour les SCA, plus précisément les
résultats d’APTOR en France.
Méthodes.— Les patients consécutifs se présentant avec un SCA nécessitant une ICP ont été
inclus entre janvier et août 2007. Les traitements et les événements cliniques ont été collectés
entre le SCA initial et le suivi à 12mois.
Résultats.— En France, le diagnostic initial était un angor instable/infarctus du myocarde sans
sus-décalage du segment ST (UA/NSTEMI) pour 255 (53 %) patients et un infarctus du myocarde
avec sus-décalage du segment ST (STEMI) pour 228 (47 %) patients. Quatre-vingt seize pour cent
ont eu une ICP avec implantation de stent. Les stents actifs étaient moins souvent utilisés
en France (22 %) qu’en Espagne (54 %) ou qu’en Angleterre (42 %). En France, les traitements
antiplaquettaires étaient plus souvent prescrits dans l’ambulance (21 %) ; la dose de charge
d’aspirine 200-299mg était la plus souvent prescrite (50 %) et plus d’un tiers des patients
ont rec¸u une dose de charge de clopidogrel supérieure à 300mg (34%). À 12mois en France,
86 % des patients prenaient toujours l’aspirine, 75 % le clopidogrel et 73 % l’association des
deux.
Conclusion.— D’importantes disparités existaient entre les pays pour la prise en charge des
SCA. Ces résultats permettent d’illustrer les pratiques des médecins et de les comparer aux
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Background
ACS is an umbrella term for a set of pathophysiological car-
diovascular signs and symptoms and is a leading cause of
morbidity and mortality in Western Europe responsible for
considerable healthcare costs [1]. ACS symptoms can be
seen as a continuum ranging from UA to NSTEMI to STEMI.
Treatment of ACS typically begins in the acute phase and
includes interventional therapy with PCI or CABG as well as
antithrombotic treatment. The oral antiplatelets aspirin and
clopidogrel are considered the baseline standard of care.
The ACC/AHA and ESC guidelines recommend early diag-
nostic cardiac catheterisation and PCI within 2 hours for
STEMI patients and 72 hours for NSTEMI patients, together
with dual antiplatelet therapy for at least 12months [2—6].
Despite the availability of guideline recommendations, vari-
ation in ACS management and PCI practice patterns are
b
i
u
Fs droits réservés.
vident between countries. Although a number of studies
n ACS management have been published, speciﬁc details
n European patient management strategies, particularly
eyond hospital discharge, are lacking.
The APTOR was a 12-month, prospective, observational
tudy of ACS patients undergoing PCI between January
nd August 2007 in three European countries: France,
pain, and the UK. The main purpose of APTOR was
o provide ‘real world’ information on country-speciﬁc
atterns of healthcare use in ACS patients, to pro-
ide a benchmark for comparison with current guidelines
nd therefore ultimately direct future patient care. The
esearchers were also interested in exploring variations
etween countries. The purpose of this current manuscript
s to evaluate treatment practice patterns in ACS patients
ndergoing PCI, focusing on APTOR study results from
rance.
1 J. Ferrières et al.
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ethods
thical conduct of the study
he study was carried out in accordance with guidelines
or Good Clinical Practice and Good Pharmacoepidemiology
ractices. The study was approved wherever required by
aw by an independent ethics committee. All patients gave
ritten consent to release information.
tudy design
ull details of the APTOR methods and population are
eported elsewhere [7]. Brieﬂy, APTOR was a 12-month, non-
nterventional, prospective, observational, cohort study
hat enrolled patients presenting with ACS and requir-
ng PCI between January and August 2007 at 122 sites
n France (71 sites), Spain (22 sites), and the UK (29
ites). Data were collected about country-speciﬁc patterns
f healthcare use in ACS patient management at teach-
ng and non-teaching centres. In France, in order to get
broad representation of ACS patients, all interventional
ardiologists from all coronary angioplasty units (approx-
mately 1000) were solicited by mail to participate and
ere asked to enrol on an average of 10 consecutive pre-
enting patients with no more than 30 patients per site. In
he other countries, fewer sites were solicited and were
sked to enrol more patients. Following enrolment, patient
are and treatment strategies were at the discretion of the
hysician.
tudy population
atients were required to be at least 18 years of age with
diagnosis of ACS requiring PCI with either initiation or
ontinuation of any antiplatelet therapy. Patients who were
imultaneously participating in another study including an
nvestigational drug or procedure were excluded from this
tudy. Once the study was initiated at a site, all consecutive
resenting ACS patients who were undergoing PCI with asso-
iated antiplatelet therapy were invited to join the study.
utcome measures
he study design is shown in Fig. 1. Demographic character-
stics, medical history, qualifying ACS diagnosis (UA, NSTEMI,
r STEMI), clinical characteristics, medical treatments and
rocedures, and clinical outcomes were recorded for each
atient using an electronic web-based data collection sys-
em at hospital admission (baseline), time of PCI, hospital
ischarge, and at follow-up at 3months after hospital dis-
harge and 12months after PCI. In-hospital measures were
ollected by review of hospital records by trained nurses and
hysicians. Postdischarge data were collected by primary
are physicians.
tatistical methodshe data were evaluated by standard exploratory and
escriptive summary statistics: median, IQR, frequency,
nd percentage. P values, ORs, and 95% CIs are reported
or comparisons between France and the two combined
c
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Figure 1. Study design. CRO: contract research organisation; PCI:
ercutaneous coronary intervention; T: time.
ountries, Spain and the UK; these are taken from logis-
ic regression models which adjusted the country difference
y potential confounders (the models included age, type
f qualifying ACS, weight, sex, and past medical history).
ogistic regression models were run to compare country dif-
erences on use of drug eluting stents, time from ACS to PCI
n STEMI and UA/NSTEMI patients, clopidogrel loading dose
dministered in the ambulance, clopidogrel use before ACS
vent, statin use before ACS event, and dual antiplatelet
se at 12months. Analyses were done using SAS version 9.1.
esults
atients studied
ne thousand ﬁve hundred and sixty-three ACS patients
ere enrolled into the full APTOR study; of these, 1525
atients (98%) were eligible for analysis. In France,
97 patients were enrolled by 59 interventional cardiologists
rom public university hospitals (36%), public non-university
ospitals (45%), and private hospitals (19%). 483 patients
97%) were eligible for analysis. Of the 14 patients (3%)
ot eligible for analysis, the reasons for exclusion were:
atient did not have an ACS diagnosis (n = 11), patient did
ot present within the normal course of care for PCI (n = 9),
nd patient did not provide consent to release information
n = 3); note: patients could have more than one reason for
xclusion.
Demographic and baseline characteristics by qualifying
CS event and country are summarised in Table 1. The
rench cohort had a median age of 59 years compared with
2 years for both Spain and the UK. The French cohort also
ad the lowest number of female patients and rates of pre-
ious vascular events and procedures, MI, and stroke.
Among French patients, the qualifying ACS diagnosis was
A in 85 patients (18%), NSTEMI in 170 patients (35%), and
TEMI in 228 patients (47%). A STEMI diagnosis was more
ommon in France than in Spain or the UK, and in the overall
PTOR population (38%). On average, STEMI patients had the
owest age and rate of cardiovascular risk factors including
iabetes and previous MI compared with NSTEMI patients in
rance.
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Table 1 Demographic and baseline characteristics.
France Other countries
Qualifying ACS event
UA/NSTEMI (n = 255) STEMI (n = 228) Total (n = 483) Spain (n = 538) UK (n = 504)
Qualifying ACS event, n (%)
UA/NSTEMI — — 255 (52.8) 361 (67.1) 327 (64.9)
STEMI — — 228 (47.2) 177 (32.9) 177 (35.1)
Age, years
Median (IQR) 61 (54, 72) 58 (50, 69) 59 (52, 71) 62 (53, 72) 62 (53, 70)
≥ 75 years, n (%) 51 (20.0) 36 (15.8) 87 (18.0) 99 (18.4) 70 (13.9)
Sex, n (%)
Male 215 (84.3) 182 (79.8) 397 (82.2) 420 (78.1) 371 (73.6)
Female 40 (15.7) 46 (20.2) 86 (17.8) 118 (21.9) 133 (26.4)
Median (IQR) height, cm — — 170 (165, 176) 167 (160, 172) 170 (164, 178)
Median (IQR) weight, kg — — 79 (70, 90) 78 (70, 85) 81 (71, 92)
Median (IQR) BMI 27.0 (24.2, 29.7) 26.9 (24.6, 29.7) 27.0 (24.5, 29.7) 27.9 (25.7, 30.8) 27.7 (24.8, 30.7)
Previous diagnosis of vascular event, n (%) — — 123 (25.5) 236 (43.9) 197 (39.1)
Undergone previous vascular procedures, n (%) — — 83 (17.2) 113 (21.0) 98 (19.4)
Medical history, n (%)
Diabetes 50 (19.6) 28 (12.3) 78 (16.1) 165 (30.7) 62 (12.3)
Previous MI 38 (14.9) 18 (7.9) 56 (11.6) 148 (27.5) 129 (25.6)
Previous stroke 4 (1.6) 3 (1.3) 7 (1.5) 13 (2.4) 13 (2.6)
ACS: acute coronary syndromes; BMI: body mass index; IQR: interquartile range; NSTEMI: non-ST-segment elevation myocardial infarction; MI: myocardial infarction; STEMI: ST-segment
elevation myocardial infarction; UA: unstable angina; UK: United Kingdom.
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Table 2 Revascularisation and stent use, and timing of PCI relative to ACS event.
France (n = 483) Spain (n = 538) UK (n = 504)
PCI procedure, n (%) 481 (99.6) 533 (99.1) 489 (97.0)
With stent, n (%) 462 (95.7) 521 (96.8) 428 (84.9)
BMS 305 (63.1) 143 (26.6) 187 (37.1)
DES 104 (21.5) 290 (53.9) 209 (41.5)
BMS + DES 48 (9.9) 85 (15.8) 27 (5.4)
> 1 stent 165 (35.7) 245 (47.0) 179 (41.8)
Days from ACS event to PCI
All patients, median (IQR) 1 (0, 2) 1 (0, 4) 4 (1, 8)
STEMI < 1 day, n (%) 136 (60.7)a 98 (57.7) 65 (39.2)
UA/NSTEMI ≤ 3 days, n (%) 202 (81.1)b 214 (64.9) 91 (31.6)
ACS: acute coronary syndromes; BMS: bare metal stent; DES: drug eluting stent; IQR: interquartile range; NSTEMI: non-ST-segment
elevation myocardial infarction; PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction; UA:
unstable angina; UK: United Kingdom.
a France versus Spain and the UK: odds ratio 2.180; 95% conﬁdence interval 1.462, 3.249; p = 0.0001.
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evascularisation and stent use
n the APTOR study overall, 1504 patients (99%) underwent
CI and 1411 patients (93%) underwent stent implantation.
Revascularisation and stent use by country is shown in
able 2. In France, 96% of patients received stents compared
ith 85% in the UK and 97% in Spain. The use of DES was
onsiderably lower in France (22%) than in Spain (54%) or
he UK (42%; France versus Spain and the UK: OR 0.28;
5%CI 0.22, 0.37; p < 0.0001). In France, and in the APTOR
tudy overall, more than one stent was used in approxi-
ately one third of patients. Stent use was the same in
A/NSTEMI and STEMI patients in France (96%), but slightly
igher in STEMI patients in APTOR overall (UA/NSTEMI: 91%;
TEMI: 95%).
The number of STEMI patients who received their PCI on
he same day as their qualifying ACS event was higher in
rance (60%) than in Spain (57%) and the UK (39%; France ver-
us Spain and the UK: OR 2.18; 95%CI 1.46, 3.25; p = 0.0001;
able 2). The number of UA/NSTEMI patients who received
heir PCI within 3 days of their qualifying ACS event date was
lso higher in France (81%) than in Spain (63%) and the UK
31%; France versus Spain and the UK: OR 5.04; 95%CI 3.52,
.24; p < 0.0001; Table 2).
Among STEMI patients, the median time from hospital
dmission to PCI was the day of admission in France (IQR 0, 1)
nd Spain (IQR 0, 2) compared with 1 day after admission
IQR 0, 4) in the UK. Among UA/NSTEMI patients, the median
ime from hospital admission to PCI was 1 day (IQR 1, 2) in
rance compared with 2 days (IQR 0, 4) in Spain and 5 days
IQR 2, 9) in the UK.
dmission and discharge cardiovascular
edications
ardiovascular medications administered before the qual-
fying ACS event and at hospital discharge are presented
or France, Spain, and the UK in Fig. 2. Patients in France
a
i
c
a
1erval 3.515, 7.237; p< 0.0001.
eported the lowest use of medications before the ACS
vent compared with Spain and the UK. Of particular note
s the large difference in statin use between the coun-
ries (France 27%, Spain 39%, UK 45%; France versus Spain
nd the UK: OR 0.52; 95%CI 0.39, 0.70; p < 0.0001). There
as no difference in clopidogrel use before the ACS event
etween France and Spain and the UK (OR 0.76; 95%CI 0.54,
.06; p = 0.1056). Discharge medication rates were similar
etween the three countries.
ntiplatelet therapy and patterns of use
or most patients in France antiplatelet therapy was initi-
ted with aspirin (91%) and clopidogrel (95%). Some patients
lso received tiroﬁban (18%), abciximab (16%), bivalirudin
3%), and eptiﬁbatide (3%). Antiplatelet use was generally
imilar in the other countries; however, there were clear
ariations in location of administration, timing of admin-
stration, and dose. At hospital discharge, 92% of patients
cross all countries were prescribed dual antiplatelet ther-
py (aspirin and clopidogrel).
In France, patients were treated quickly with both aspirin
nd clopidogrel. Aspirin loading and maintenance doses
t hospital discharge are shown in Table 3. Most patients
eceived their aspirin-loading dose in the ambulance (26%),
he intensive care unit (25%), or the emergency room (24%).
spirin was more likely to be given in the ambulance in
TEMI (39%) rather than UA/NSTEMI (15%) patients. Com-
ared with France, the rates for receiving aspirin in the
mbulance were lower in Spain (6%) but slightly higher in
he UK (32%). 83% of patients in France (n = 355) received
spirin before PCI (Table 3). Patients in France most fre-
uently received a 200—299mg loading dose of aspirin (50%)
nd a ≤ 100mg maintenance dose (57%; Table 3). Patients
n France were more likely to receive a high aspirin dis-
harge maintenance dose (≥ 150mg) compared with Spain
nd the UK; this was mainly accounted for by doses of
60mg (UA/NSTEMI: 39%; STEMI: 30%) with only one STEMI
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aFigure 2. Cardiovascular medications at admission, discharge, a
angiotensin-converting enzyme inhibitor; ACS: acute coronary synd
intervention; UK: United Kingdom.
patient receiving the highest dose of 300mg. In addition,
non-diabetic patients were more likely to receive higher
aspirin discharge doses; for example, the one STEMI patient
in France who received the highest aspirin discharge dose
was non-diabetic, and more non-diabetic versus diabetic
patients received the highest dose in both Spain (7% versus
4%) and the UK (7% versus 6%).
In France, 87% of patients (n = 393) received their clopi-
dogrel loading dose before PCI; either in the intensive care
unit (32%), the emergency room (24%), or the ambulance
(21%; Fig. 3). The rates for receiving the drug in the ambu-
lance were notably higher in STEMI (32%) than UA/NSTEMI
(11%) patients in France, and lower in the total population in
Spain (2%) and the UK (< 1%; France versus Spain and the UK:
OR 24.64; 95%CI 12.15, 49.95; p < 0.0001). Distribution of
dose data in Table 3 shows that patients in France most fre-
quently received a 300mg loading dose (on label dosage) of
clopidogrel (53%), one third were treated with a loading dose
greater than 300mg (34%), and 14% received a loading dose
lower than 300mg. For chronic treatment, three quarters
L
I
(2months after PCI in France (A), Spain (B), and the UK (C). ACE:
; ARB: angiotensin 2 receptor blocker; PCI: percutaneous coronary
f the patients received a 75mg maintenance dose (77%;
n label dosage) and the remaining patients (23%) received
150mg maintenance dose. More French patients received
igher loading (> 300mg) and maintenance (150mg) doses
han the Spanish and UK patients; in fact, only one patient
n each of Spain and the UK received the 150mg clopidogrel
aintenance dose.
Glycoprotein IIb/IIIa inhibitor (GPI IIb/IIIa) use is shown
y country in Fig. 4. 172 patients (36%) in France received
PI IIb/IIIa; this was slightly lower in Spain and the UK.
iroﬁban was the GPI IIb/IIIa used most frequently in France
18%) followed by abciximab (16%) and eptiﬁbatide (3%).
bciximab was more frequently given in Spain and the UK
ollowed by tiroﬁban and eptiﬁbatide. The highest rate of
bciximab use was observed in STEMI patients.ength of hospitalisation
n France, the median length of stay in hospital was 5 days
IQR 3, 7 days); this was primarily accounted for by time
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Table 3 Antiplatelet treatment and time to stopping treatment in the 12months following PCI.
France (n = 483) Spain (n = 538) UK (n = 504)
Aspirin
Loading dose, n (%)
0—199mg 89 (21.7) 217 (47.7) 46 (10.7)
200—299mg 205 (50.0) 31 (6.8) 3 (0.7)
300+mg 116 (28.3) 207 (45.5) 381 (88.6)
Timing of loading dose relative to PCI, n (%)
More than 24 hours before PCI 123 (27.8) 293 (59.9) 278 (62.6)
13 to 24 hours before PCI 59 (13.3) 35 (7.2) 27 (6.1)
7 to 12 hours before PCI 34 (7.7) 22 (4.5) 18 (4.1)
1 to 6 hours before PCI 139 (31.4) 79 (16.2) 106 (23.9)
At time of PCI 60 (13.6) 53 (10.8) 4 (0.9)
After PCI 27 (6.1) 7 (1.4) 11 (2.5)
Maintenance dose at hospital discharge, n (%)
< 100mg 265 (57.0) 2 (0.4) 444 (92.3)
100—150mg 22 (4.7) 462 (93.0) 4 (0.8)
> 150mg 178 (38.3) 33 (6.6) 33 (6.9)
Patients no longer taking aspirin 12months after PCI, n 53 17 53
Median (IQR) time to stopping, days 30 (30, 128) 28 (1, 32) 98 (28, 175)
Clopidogrel
Loading dose, n (%)
< 300mg 59 (13.5) 134 (27.7) 43 (9.3)
300mg 230 (52.6) 273 (56.4) 324 (70.1)
> 300mg 148 (33.9) 77 (15.9) 95 (20.6)
Timing of loading dose relative to PCI, n (%)
More than 24 hours before PCI 134 (29.1) 231 (45.6) 289 (60.0)
13 to 24 hours before PCI 72 (15.7) 38 (7.5) 34 (7.1)
7 to 12 hours before PCI 36 (7.8) 16 (3.2) 22 (4.6)
1 to 6 hours before PCI 151 (32.8) 56 (11.0) 110 (22.8)
At time of PCI 49 (10.7) 153 (30.2) 20 (4.1)
After PCI 18 (3.9) 13 (2.6) 7 (1.5)
Maintenance dose at hospital discharge, n (%)
75mg 357 (77.3) 499 (99.6) 467 (99.8)
150mg 105 (22.7) 1 (0.2) 1 (0.2)
Patients no longer taking clopidogrel 12months after PCI, n 83 120 131
Median (IQR) time to stopping, days 90 (30, 182) 109 (30, 180) 84 (28, 177)
IQR: interquartile range; PCI: percutaneous coronary intervention; UK: United Kingdom.
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apent in the coronary care unit. Median length of hospital-
sation was generally similar among countries (5 days [IQR
, 8 days] in Spain; 5 days [IQR 3, 9 days] in the UK) and
etween UA/NSTEMI (4 days [IQR 3, 7 days] in France, 5 days
IQR 2, 7 days] in Spain, and 6 days [IQR 3, 10 days] in the
K) and STEMI (5 days [IQR 4, 8 days] in France; 6 days [IQR
, 8 days] in Spain, and 4 days [IQR 3, 8 days] in the UK)
atients.2-month follow-up
ollow-up data to 12months were available for 394 patients
81%) in France compared with 497 patients (92%) in Spain
nd 444 patients (85%) in the UK. The most common reasons
F
1
g
a
aor discontinuation in France were patient lost to follow-
p (9%) and physician decision (7%). Discontinuations mainly
ccurred during the ﬁnal follow-up to 12months post PCI.
rance had more patients lost to follow-up than either Spain
6%) or the UK (5%).
Most of the treatments received at hospital discharge for
ardiovascular risk were maintained at 12months (Fig. 2).
ntiplatelet treatment continuation rates over 12months
re shown for France, Spain, and the UK in Fig. 5. In
rance, 337 patients (86%) were still receiving aspirin at
2months, 297 patients (75%) were still receiving clopido-
rel, and 287 patients (73%) were still receiving combination
spirin and clopidogrel. Continuation rates were higher for
spirin in Spain (95%) but similar in the UK (86%), slightly
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Most patients underwent PCI and stent implantation. DES,Figure 3. Location of clopidogrel loading dose in France, Spain,
and the UK. UK, United Kingdom.
lower for clopidogrel in Spain (70%) and the UK (66%), and
lower for combination treatment in both other countries
(Spain, 68%; UK, 63%; France versus Spain and the UK:
OR 2.06; 95%CI 1.51, 2.82; p < 0.0001).
In France, approximately two thirds of patients still
receiving treatment at 12months after PCI had no treatment
interruptions (aspirin: 66%; clopidogrel: 65%). However, the
proportion of patients with no interruptions was higher in
Spain and the UK for both aspirin (Spain: 99%; UK: 88%) and
clopidogrel (Spain: 99%; UK: 88%). Among French patients
still treated with antiplatelets 12months after PCI, most
patients who received aspirin remained on the same main-
tenance dose; however, for clopidogrel, maintenance dose
was decreased during follow-up for most patients (n = 59)
receiving 150mg at discharge and was not changed for most
patients (n = 220) receiving 75mg at discharge. In both Spain
and the UK, 90% of patients remained on the same aspirin
maintenance dose and 99% remained on the same clopido-
grel maintenance dose (mainly 75mg).
The median time to stopping aspirin and clopidogrel
treatment is shown by country in Table 3. In France, among
patients who stopped clopidogrel before 12months, 48%
discontinued during the ﬁrst 3months. Among patients no
longer treated at 12months after PCI, the median times to
stopping treatment were 30 days for aspirin and 90 days for
clopidogrel. Stopping times for clopidogrel were shorter for
STEMI (median, 30 days; n = 39) than for UA/NSTEMI (median,
121 days; n = 44) patients. Results were similar in Spain and
the UK for clopidogrel, but UK patients had a much longer
median stopping time for aspirin compared with France and
Spain. More patients with BMS stopped taking clopidogrel
within 12months (25%) compared with those who had DES
(14%). This was also the case in Spain and the UK and in
APTOR overall.
w
r
ligure 4. Glycoprotein IIb/IIIa inhibitors use in France, Spain,
nd the UK. GPI IIb/IIIa, glycoprotein IIb/IIIa inhibitor; UK, United
ingdom.
In France, 23 patients (6%) had planned hospital read-
issions and in more than half of cases (52%) a PCI was
one during these readmissions. Fifty-four patients (14%)
ad unplanned hospital readmissions due to cardiovascu-
ar events; 31 (57%) of these had a PCI, 3 (6%) had a
ABG, and 13 (24%) were readmitted two or more times.
ix patients (1%) had planned hospital readmissions in Spain
nd 42 (9%) had unplanned readmissions due to cardiovascu-
ar events, whereas in the UK, 13 (3%) and 45 (10%) patients
ad planned and unplanned readmissions, respectively. The
verall death rate was low and comparable among the coun-
ries. In France there were 10 deaths (2%) compared with
4 deaths in Spain (3%) and 15 deaths in the UK (3%).
iscussion
his manuscript has described the results of the French
ohort of APTOR, a large prospective observational study
esigned to provide long-term data on the treatment man-
gement practices of ACS patients undergoing PCI, and
ompared them with the cohorts from Spain and the UK.
Although baseline characteristics were generally compa-
able between the countries, some differences were noted;
or example, the French population were younger, had more
ases of STEMI, and had lower rates of prestudy cardiovas-
ular events compared with Spain and the UK. A hypothesis
o explain this could be the selection of the participating
entres from among the more active centres which tend to
ecruit younger patients. Even so, before the qualifying ACS
vent, signiﬁcant numbers of patients were taking cardio-
ascular medications and had experienced previous events,
hich suggests recurrent events still occur at a high rate
espite the availability of treatments.hich are coated with an antiproliferative agent to help
educe the risk of restenosis, were implanted three times
ess than BMS in France, and were used much less in France
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eigure 5. Antiplatelet treatments continuation rates over 12mo
atients in each country with 12-month follow-up data. UK, United
ompared with Spain and the UK. There has been a lot of
orldwide discussion about the use of DES in recent years
nd doubts have been raised about the safety of these
evices. This has been a particularly relevant issue in France
ecause in 2008, after recruitment of the patients, the
rench Society of Cardiology reviewed the available data
nd accepted that although DES are effective in reducing
he risk of restenosis, doubts persist regarding the possibil-
ty of late thrombosis. They recommended particular care
n weighing up the risks and beneﬁts for each patient when
onsidering using a DES [8]. Moreover, lower use of DES
ould be explained by the non-recommendation of DES in
TEMI patients by the French health authority at the time
f recruitment and the higher rates of STEMI patients in the
rench cohort.
In France, the time between the occurrence of the
ualifying ACS event and the patient undergoing PCI
as short. This was especially evident in patients with
TEMI, for whom a special process seems to be in place
etween the ambulance and the catheterisation labora-
ory. This could be related to the good availability of
m
t
t
fin France (A), Spain (B), and the UK (C). N is the total number of
dom.
atheterisation laboratories in France; there are around 220
ospitals with catheterisation facilities in the country. In
rance, it seems that ESC and ACC/AHA guideline recom-
endations for the optimal treatment of acute MI, in terms
f delay from symptom onset to treatment and access to
nterventional facilities, are followed. This is important as
here is evidence that compliance with guidelines for early
eperfusion therapy has a proven beneﬁt in reducing mor-
ality in patients with STEMI [9].
The rates and patterns of baseline medication use reﬂect
he incidence of cardiovascular diseases in the different
ountries. The lower rate of previous statin use observed
n France compared with the UK may reﬂect higher disease
ates in the UK. Epidemiological studies repeatedly show
igher rates (up to three times) of MI in the UK compared
ith France [10], which could possibly be related to differ-
nces in diet and lifestyle between these countries. There
ay also be the contextual effect of the ‘French paradox’;
he observation that despite a high intake of dietary choles-
erol and saturated fat in France there is a low death rate
rom CHD. This is inconsistent with the known risk factors
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for CHD and is thus paradoxical and therefore could suggest
that there are protective behaviours speciﬁc to France that
help reduce CHD incidence. The exact nature of these pro-
tective factors is under debate, although wine drinking and
attitudes to food may be an important component [11]. On
the other hand, the prescription of statins in France for pri-
mary prevention is limited by the AFSSAPS guidelines [12],
whereas they are commonly used for primary preventative
care in the UK. Furthermore, a selection bias of patients
with a low history of previous MI in France may also be a
further explanation of such ﬁndings.
Most patients received appropriate antiplatelet ther-
apy following their qualifying ACS event. However, there
was variation in the location of administration, the tim-
ing of administration, and dosing of aspirin and clopidogrel
between the three countries. Antiplatelet therapy was much
more frequently given in the ambulance in France than in
Spain or the UK. This could be related to the system in France
in which treatment starts quickly in the ambulance, or the
nature of the ACS event as there were more STEMI cases in
France, which requires rapid treatment initiation. Regarding
the timing of antiplatelet treatment, patients were treated
very quickly in France, this again seems to be related to
the current system and facilities available. ESC guidelines
recommend an aspirin-loading dose of 150—325mg and a
maintenance dose of 75—100mg, and a clopidogrel loading
dose of 300mg and a maintenance dose of 75mg. Despite
this guidance, variation in practice was evident by country,
including somewhat higher doses being used in France, par-
ticularly with aspirin. These practices could be related to
the extensive use of antiplatelet resistance tests in France
[13]. This is in contrast to the large observational PCI-CURE
analysis in which lower doses of aspirin were found to be as
effective as higher doses in preventing ischaemic events but
with the advantage of fewer adverse bleeding events [14].
The length of patient hospitalisation was generally
similar between the countries, which suggests that the
observed differences in patient management strategies may
not signiﬁcantly impact the duration of in-hospital treat-
ment needed. At hospital discharge, most patients received
established therapies and almost all received antiplatelet
treatments, but there were still between-country variations
in dose; most notably, patients in France were more likely
to have received higher discharge doses.
Most cardiovascular treatments received at hospital
discharge were maintained over the 12month follow-up.
Patients in France had the longest length of clopidogrel
therapy, although they also had more treatment interrup-
tions. ESC guidelines recommend maintaining dual therapy
with both clopidogrel and aspirin for at least 12months.
However, stopping medication is common in cardiovascular
disease patients and has been linked to increased rates of
ischaemic events and mortality [15,16]. One study evalu-
ated medication patterns following MI and found that use of
recommended medications, such as beta-blockers, aspirin
and/or clopidogrel, statins, and angiotensin-converting
enzyme inhibitors or angiotensin-receptor blockers in France
is satisfactory, although not optimal [17]. In the current
study, continued use of clopidogrel at 12months was lower
in patients who received BMS; however, guidelines recom-
mend 12months of clopidogrel in ACS patients treated with
PCI irrespective of the type of stent used.
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One other interesting ﬁnding was the absence of differ-
nces in the outcomes between countries despite the very
ifferent patient management practices. The low rate of
linical outcomes could be due to the data collection modal-
ties used by physicians who may have missed some events
nd also because patients’ deaths may have occurred out-
ide the hospital [18].
APTOR is one of the ﬁrst studies to provide data on
CS treatment practices in Europe. Non-experimental obser-
ational studies such as APTOR reﬂect real-life practice,
elp us to understand the natural history and impact of
herapy, and are more reﬂective of the experiences of
he patient. However, with observational studies, there is
lways a potential for bias (in the design, data collection,
nd analysis) and subjective interpretation of the data,
hich can undermine the quality of the results. ACS patients
n the French APTOR study population were different from
he Spanish and UK populations because they had a younger
edian age, more STEMI cases, and lower rates of vascular
isease, diabetes, and previous medication use. Selection
ias was highly probable in the APTOR study; there was a
election bias between countries as the selection of centres
as different and thus there were differences in the base-
ine characteristics of the recruited patients, and the low
ortality rate suggests a general selection bias of patients
ithin the study. However, the demographic characteristics
nd clinical features of the French study population are
n agreement with epidemiological results from the MON-
CA study of 2018 ACS patients hospitalised in three regions
n France and the 2005 FAST-MI registry of 3059 acute MI
atients [19,20]. In both of these studies, the study popula-
ions had a high rate of STEMI (MONICA, 60%; FAST-MI, 52%)
nd the MONICA study also had a population with a low age
mean of 57.2 years).
onclusions
he long-term data supplied by this study reﬂect ‘real world’
reatment practice patterns of ACS patients managed by PCI
n France, and provide a useful benchmark for comparison
ith data from other European countries and current guide-
ines. This in turn should help direct future patient care and
trengthen efforts to achieve international best practice.
n important ﬁnding is that there is considerable variation
n the treatment of patients between the three European
ountries. The features of the treatment received by French
atients is reﬂective of the system in France; for example,
reatment is received quickly in France with the ﬁrst doses
f antiplatelet therapy often received in the ambulance and
CI typically carried out on the day of hospital admission.
n addition, the lower use of DES in France could be related
o recent concerns about their safety. This study suggests
hat standards in the current European guidelines for ACS
anagement are generally being met in France.onﬂict of interest statement
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